PMID- 36969321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230328
IS  - 2405-5808 (Electronic)
IS  - 2405-5808 (Linking)
VI  - 34
DP  - 2023 Jul
TI  - Hypoxia-treated umbilical mesenchymal stem cell alleviates spinal cord 
      ischemia-reperfusion injury in SCI by circular RNA circOXNAD1/ miR-29a-3p/ FOXO3a 
      axis.
PG  - 101458
LID - 10.1016/j.bbrep.2023.101458 [doi]
LID - 101458
AB  - Spinal cord ischemia reperfusion (SCIR) injury leads to spinal cord function 
      injury, neural dysfunction and sometimes paralysis or even paraplegia, which 
      severely impair the physical and mental health of individuals. Mesenchymal stem 
      cells (MSCs) are a group of stem cells that have been widely studied for 
      treatment of various diseases. This work aimed to study the therapeutic potential 
      of hypoxia-induced exosomal circular RNA OXNAD1 from human umbilical cord 
      mesenchymal stem cells (HucMSCs) against SCIR. We established an in vivo rat 
      spinal cord injury (SCI) model and conducted treatment with exosomes that 
      isolated from hypoxia-HucMSCs. Hypoxia-HucMSCs-derived exosomal circOXNAD1 
      alleviated the spinal cord tissue injury in SCI, improved limb motor function, 
      decreased production of inflammatory factors including the IL-1 beta, IL-6, and 
      TNF-alpha. The in vitro hypoxia and reoxygenation (H/R) model demonstrated that 
      Hypoxia-HucMSCs-derived exosomal circOXNAD1 improved neuron proliferation and 
      alleviated apoptosis. Mechanistically, circOXNAD1 directly interact with 
      miR-29a-3p and miR-29a-3p targets the 3'UTR of FOXO3a in neurons. Inhibition of 
      miR-29a-3p and overexpression of FOXO3a reversed the effects of circOXNAD1 
      depletion in PC12 cell phenotypes. In conclusion, Hypoxia elevated the level 
      circOXNAD1 in exosomes that derived from HuMSCs. The exosomal circOXNAD1 
      alleviated SCI through sponging miR-29a-3p and consequently elevated the FOXO3a 
      expression. Our findings provided novel evidence for MSC-derived exosomal 
      circOXNAD1in the treatment of SCI.
CI  - (c) 2023 Everunion Biotechnology Co., LTD. Tianjin.
FAU - Wang, Xiujuan
AU  - Wang X
AD  - Technology Department, Everunion Biotechnology Co. LTD., Tianjin, China.
FAU - Li, Wei
AU  - Li W
AD  - Technology Department, Everunion Biotechnology Co. LTD., Tianjin, China.
FAU - Hao, MingYuan
AU  - Hao M
AD  - Technology Department, Everunion Biotechnology Co. LTD., Tianjin, China.
FAU - Yang, Ying
AU  - Yang Y
AD  - Technology Department, Everunion Biotechnology Co. LTD., Tianjin, China.
FAU - Xu, YongSheng
AU  - Xu Y
AD  - Technology Department, Everunion Biotechnology Co. LTD., Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20230320
PL  - Netherlands
TA  - Biochem Biophys Rep
JT  - Biochemistry and biophysics reports
JID - 101660999
PMC - PMC10033311
OTO - NOTNLM
OT  - Exosomes
OT  - FOXO3
OT  - Ischemia-reperfusion injury
OT  - Mesenchymal stem cell
OT  - Spinal cord injury
OT  - circOXNAD1
OT  - miR-29a-3p
COIS- There are no conflicts of interest.
EDAT- 2023/03/28 06:00
MHDA- 2023/03/28 06:01
PMCR- 2023/03/20
CRDT- 2023/03/27 03:36
PHST- 2022/11/30 00:00 [received]
PHST- 2023/02/28 00:00 [revised]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/03/27 03:36 [entrez]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/28 06:01 [medline]
PHST- 2023/03/20 00:00 [pmc-release]
AID - S2405-5808(23)00039-0 [pii]
AID - 101458 [pii]
AID - 10.1016/j.bbrep.2023.101458 [doi]
PST - epublish
SO  - Biochem Biophys Rep. 2023 Mar 20;34:101458. doi: 10.1016/j.bbrep.2023.101458. 
      eCollection 2023 Jul.